Skip to main content
SpringerLink
Log in

Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer

  • Original Articles
  • Razoxane Colorectal Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

One hundred and seventy six patients (81 controls, 95 receiving treatment) have entered a prospective randomized tiral of long-term oral adjuvant razoxane (ICRF-159) following removal of a colorectal cancer. The median follow-up is 34 months. The treated patients in Dukes' groups B and C have a significantly longer disease-free interval than the control patients (P=0.01 ‘as randomized’ and P=0.004 ‘as treated’). The differences in survival for Dukes' groups B and C are not significant, although follow-up is short. In Dukes' groups B and C, however, 24 of 56 of the patients in the control group have died (43%), as against only 17 of 64 in the treatment group (27%). The treatment produces very few side-effects, is well tolerated by patients, and is taken orally.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bakowski MT (1976) ICRF 159, (±)1,2-di(3,5-dioxo piperazin-l-yl)propane NSC-129,943; Razoxane. Cancer Treat Rev 3:95–197

    Google Scholar 

  2. Bellet RE, Engstrom PF, Catalano RB, Creech RH, Mastrangelo MJ (1976) Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep 60:1395–1397

    Google Scholar 

  3. Berge T, Ekelund G, Mellner C, Pihl B, Wenckert A (1973) Carcinoma of the colon and rectum in a defined population. Acta Chir Scand [Suppl] 438

  4. Davis HL, Kisner DL (1978) Analysis of adjuvant therapy in large bowel cancer. Cancer Clin Trials 1:273–287

    Google Scholar 

  5. Dukes CE (1944) The surgical pathology of rectal cancer. Proc R Soc Med 37:131–144

    Google Scholar 

  6. Dukes CE, Bussey HJR (1958) The spread of rectal cancer and its effect on prognosis. Br J Cancer 12:309–320

    Google Scholar 

  7. Fielding LP, Stewart-Brown S, Dudley HAF (1978) Surgeon-related variables and the clinical trial. Lancet 2:778–779

    Google Scholar 

  8. Gill PG, Morris PJ (1978) The survival of patients with colorectal cancer treated in a regional hospital. Br J Surg 65:17–20

    Google Scholar 

  9. Grage TB, Hill GJ, Cornell GN, Frelick RW, Moss SE (1979) Adjuvant chemotherapy in large bowel cancer — Updated analysis of single-agent chemotherapy. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer, vol II. Grune & Stratton, New York, pp 587–594

    Google Scholar 

  10. Hallowes RC, West DG, Hellmann K (1974) Cumulative cytostatic effect of ICRF-159. Nature 247:487–490

    Google Scholar 

  11. Hellmann K, Burrage K (1969) Control of malignant metastases by ICRF 159. Nature 224:273–275

    Google Scholar 

  12. Higgins GA Jr, Lee LE, Dwight RW, Keehn RJ (1978) The case for adjuvant 5-fluorouracil in colorectal cancer. Cancer Clin Trials 1:35–41

    Google Scholar 

  13. Le Serve AW, Hellmann K (1972) Metastases and the normalization of tumour blood vessels by ICRF 159: A new type of drug action. Br Med J I:597–601

    Google Scholar 

  14. Marciniak TA, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ (1975) Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma. Cancer Chemother Rep 59:761–763

    Google Scholar 

  15. McDermott FT, Hughes ESR, Pihl EA, Milne BJ (1980) Changing survival prospects in carcinoma of the rectum. Br J Surg 67:775–780

    Google Scholar 

  16. Moertel CG (1978) Chemotherapy of gastrointestinal cancer. N Engl J Med 299:1049–1052

    Google Scholar 

  17. Paul AR, Catalano RB, Engstrom PF (1980) Phase III study of ICRF-159 versus 5FU in the treatment of advanced metastatic colorectal carcinoma. Cancer Treat Rep 64:1047–1049

    Google Scholar 

  18. Peto R, Pike MC, Armitage P, et al (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1–39

    CAS  PubMed  Google Scholar 

  19. Salsbury AJ, Burrage K, Hellmann K (1970) Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic. Br Med J IV:344–346

    Google Scholar 

  20. Salsbury AF, Burrage K, Hellmann K (1974) Histological analysis of the antimetastatic effect of (±)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res 34:843–849

    Google Scholar 

  21. Spratt JS, Spjut HJ (1967) Prevalence and prognosis of individual clinical and pathological variables associated with colorectal carcinoma. Cancer 20:1976–1985

    Google Scholar 

  22. Talbot IC, Ritchie S, Leighton MH, Hughes AO, Bussey HJR, Morson BC (1980) The clinical significance of invasion of veins by rectal cancer. Br J Surg 67:439–442

    Google Scholar 

  23. Willis RA (1960) In: Pathology of tumours, 3rd edn. Butterworths, London, p 427

    Google Scholar 

  24. Wood DA, Robbins GF, Zippin C, Lum D, Stearns M (1979) Staging of cancer of the colon and cancer of the rectum. Cancer 43:961–968

    Google Scholar 

  25. Wood CB, Gillis CR, Hole D, Malcolm AJH, Blumgart LH (1981) Local tumour invasion as a prognostic factor in colorectal cancer. Br J Surg 68:326–328

    Google Scholar 

Download references

Author information

Author notes

  1. J. M. Gilbert

    Present address: Clinical Research Centre, Watford Road, HA1 3UJ, Harrow, Middlesex, Great Britain

Authors and Affiliations

  1. Wexham Park Hospital, Slough

    J. M. Gilbert & P. G. Cassell

  2. Westminster Hospital, SW1, London

    K. Hellmann, H. Ellis & C. Wastell

  3. Imperial Cancer Research Fund, WC2, London

    K. Hellmann & M. Evans

  4. Eastbourne District Hospital, Great Britain

    B. Stoodley

Authors
  1. J. M. Gilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Hellmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. G. Cassell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Stoodley
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Wastell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gilbert, J.M., Hellmann, K., Evans, M. et al. Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer. Cancer Chemother. Pharmacol. 8, 293–299 (1982). https://doi.org/10.1007/BF00254053

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254053

Keywords

Search

Navigation